Novo Nordisk released results of a late-stage trial of CagriSema, a weekly injection combining cagrilintide and semaglutide (the active ingredient in Wegovy).
The combination showed superior weight loss to the use of semaglutide alone. However, the trial failed to meet the target of demonstrating equal or superior weight loss to the maximum dose of Eli Lilly’s tirzepatide.
A more strictly controlled clinical study is still underway , and a higher dose trial is due to start later in the year. An application for medical approval of CagriSema remains with the US authorities, with a decision expected in the second half of 2026.
The shares fell 14.0% following the announcement .
Our View
HL view to follow
Novo Nordisk key facts
All ratios are sourced from LSEG Datastream, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.
This article is original Hargreaves Lansdown content, published by Hargreaves Lansdown. It was correct as at the date of publication, and our views may have changed since then. Unless otherwise stated estimates, including prospective yields, are a consensus of analyst forecasts provided by LSEG. These estimates are not a reliable indicator of future performance. Yields are variable and not guaranteed. Investments rise and fall in value so investors could make a loss.
This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment.